Anti-HER2 induced myeloid cell alterations correspond with increasing vascular maturation in a murine model of HER2+ breast cancer

BACKGROUND: Therapy targeted to the human epidermal growth factor receptor type 2 (HER2) is used in combination with cytotoxic therapy in treatment of HER2+ breast cancer. Trastuzumab, a monoclonal antibody that targets HER2, has been shown pre-clinically to induce vascular changes that can increase...

Descripción completa

Detalles Bibliográficos
Autores principales: Bloom, Meghan J., Jarrett, Angela M., Triplett, Todd A., Syed, Anum K., Davis, Tessa, Yankeelov, Thomas E., Sorace, Anna G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7189470/
https://www.ncbi.nlm.nih.gov/pubmed/32345237
http://dx.doi.org/10.1186/s12885-020-06868-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7189470/
https://www.ncbi.nlm.nih.gov/pubmed/32345237
http://dx.doi.org/10.1186/s12885-020-06868-4

Ejemplares similares